Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease

  • Park, Hyo Min (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Lee, Dong Won (Department of Pediatrics, Daegu Fatima Hospital) ;
  • Hyun, Myung Chul (Department of Pediatrics, Kyungpook National University School of Medicine) ;
  • Lee, Sang Bum (Department of Pediatrics, Kyungpook National University School of Medicine)
  • Received : 2012.07.07
  • Accepted : 2012.10.24
  • Published : 2013.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: It has been reported that 10% to 20% of children with Kawasaki disease (KD) will not respond to intravenous immunoglobulin (IVIG) treatment. In this study, we aimed to identify useful predictors of therapeutic failure in children with KD. Methods: We examined 309 children diagnosed with KD at the Kyungpook National University Hospital and the Inje University Busan Paik Hospital between January 2005 and June 2011. We retrospectively reviewed their medical records and analyzed multiple parameters in responders and nonresponders to IVIG. Results: Among the 309 children, 30 (9.7%) did not respond to IVIG. They had significantly higher proportion of neutrophils, and higher levels of aspartate aminotransferase, alanine aminotransferase (ALT), total bilirubin, and N-terminal fragment of B-type natriuretic peptide than did responders. IVIG-nonresponders had a significantly longer duration of hospitalization, and more frequently experienced coronary artery lesion, and sterile pyuria. No differences in the duration of fever at initial treatment or, clinical features were noted. Conclusion: Two independent predictors (ALT${\geq}$84 IU/L, total bilirubin${\geq}$0.9 mg/dL) for nonresponse were confirmed through multivariate logistic regression analysis. Thus elevated ALT and total bilirubin levels might be useful in predicting nonresponse to IVIG therapy in children with KD.

Keywords

References

  1. Harnden A, Takahashi M, Burgner D. Kawasaki disease. BMJ 2009;338:b1514. https://doi.org/10.1136/bmj.b1514
  2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. https://doi.org/10.1542/peds.2004-2182
  3. Royle J, Burgner D, Curtis N. The diagnosis and management of Kawasaki disease. J Paediatr Child Health 2005;41:87-93. https://doi.org/10.1111/j.1440-1754.2005.00555.x
  4. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010;8:197-203. https://doi.org/10.1586/eri.09.109
  5. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004;163:285-91. https://doi.org/10.1007/s00431-004-1431-z
  6. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  7. Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr 2008;153: 365-8. https://doi.org/10.1016/j.jpeds.2008.03.014
  8. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma- globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
  9. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
  10. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117-21. https://doi.org/10.1016/j.jpeds.2007.12.021
  11. Do YS, Kim KW, Chun JK, Cha BH, Namgoong MK, Lee HY. Predicting factors for refractory Kawasaki disease. Korean Circ J 2010; 40:239-42. https://doi.org/10.4070/kcj.2010.40.5.239
  12. Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatr 2010;99:1578-83. https://doi.org/10.1111/j.1651-2227.2010.01875.x
  13. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Hyponatremia in Kawasaki disease. Pediatr Nephrol 2006;21:778-81. https://doi.org/10.1007/s00467-006-0086-6
  14. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol 2007;22:987-91. https://doi.org/10.1007/s00467-007-0449-7
  15. Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CC, et al. Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta 1997;260:15-26. https://doi.org/10.1016/S0009-8981(96)06502-3
  16. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991;84:625-31. https://doi.org/10.1161/01.CIR.84.2.625
  17. Yun SW, Lee HS, Kim DW, Rhee KW, Jung YS. Changes of lipid and lipoprotein compositions in Kawasaki disease and its impact on cardiac complications. Korean J Pediatr 2005;48:1370-7.
  18. Davis GK, Bamforth F, Sarpal A, Dicke F, Rabi Y, Lyon ME. B-type natriuretic peptide in pediatrics. Clin Biochem 2006;39:600-5. https://doi.org/10.1016/j.clinbiochem.2005.12.004
  19. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005;11(5 Suppl):S81-3. https://doi.org/10.1016/j.cardfail.2005.04.019
  20. Newton PJ, Betihavas V, Macdonald P. The role of B-type natriuretic peptide in heart failure management. Aust Crit Care 2009; 22:117-23. https://doi.org/10.1016/j.aucc.2009.06.001
  21. Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ 2005;14:78-84. https://doi.org/10.1016/j.hlc.2005.03.002
  22. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8. https://doi.org/10.1007/s00246-008-9258-4
  23. Nasser N, Bar-Oz B, Nir A. Natriuretic peptides and heart disease in infants and children. J Pediatr 2005;147:248-53. https://doi.org/10.1016/j.jpeds.2005.03.051
  24. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail 2005;11(5 Suppl):S76-80. https://doi.org/10.1016/j.cardfail.2005.04.009
  25. Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009;30:810-7. https://doi.org/10.1007/s00246-009-9441-2
  26. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241-8. https://doi.org/10.1046/j.1442-200x.2000.01225.x

Cited by

  1. 한국인에서 면역글로불린-저항성 가와사키병 환자의 예측 vol.21, pp.1, 2013, https://doi.org/10.14776/kjpid.2014.21.1.29
  2. Use of corticosteroids during acute phase of Kawasaki disease vol.4, pp.4, 2015, https://doi.org/10.5409/wjcp.v4.i4.135
  3. Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children vol.46, pp.4, 2013, https://doi.org/10.4070/kcj.2016.46.4.542
  4. Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease vol.59, pp.2, 2013, https://doi.org/10.3345/kjp.2016.59.2.80
  5. Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease vol.60, pp.7, 2013, https://doi.org/10.3345/kjp.2017.60.7.216
  6. Verification of Current Risk Scores for Kawasaki Disease in Korean Children vol.32, pp.12, 2013, https://doi.org/10.3346/jkms.2017.32.12.1991
  7. 농뇨 동반 가와사키병의 임상적 특징 vol.24, pp.3, 2017, https://doi.org/10.14776/piv.2017.24.3.141
  8. Neutrophil-to-Lymphocyte Ratio Predicts Intravenous Immunoglobulin-Resistance in Infants Under 12-Months Old With Kawasaki Disease vol.7, pp.None, 2013, https://doi.org/10.3389/fped.2019.00081
  9. A novel model for predicting non‐responsiveness to intravenous immunoglobulins in Kawasaki disease: The Singapore experience vol.55, pp.8, 2013, https://doi.org/10.1111/jpc.14329
  10. Neutrophil-to-lymphocyte ratio as a biomarker for predicting the intravenous immunoglobulin-resistant Kawasaki disease vol.99, pp.6, 2013, https://doi.org/10.1097/md.0000000000018535
  11. Risk Factors of Intravenous Immunoglobulin Resistance in Children With Kawasaki Disease: A Meta-Analysis of Case-Control Studies vol.8, pp.None, 2020, https://doi.org/10.3389/fped.2020.00187
  12. Prediction for Intravenous Immunoglobulin Resistance Combining Genetic Risk Loci Identified From Next Generation Sequencing and Laboratory Data in Kawasaki Disease vol.8, pp.None, 2013, https://doi.org/10.3389/fped.2020.462367
  13. Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study vol.19, pp.1, 2013, https://doi.org/10.1186/s12969-021-00638-7